Omics of Male Breast Cancer

Feb 12, 2017 by in ONCOLOGY Comments Off on Omics of Male Breast Cancer

BRCA 1 CD105 BRCA 2 Survivin HER2 gene (HER2/neu or ErbB2) COX-2 MYC Ki67 ER Tropomyosins PR NAT1 BRST2 RAD51B (14q24.1) AR TOX3 (16q12.1) C-erb-2 rs13387042 (2q35) p53 rs10941679 (5p12)…

read more

Metabolomics in Breast Cancer

Feb 12, 2017 by in ONCOLOGY Comments Off on Metabolomics in Breast Cancer

Chemical shift Multiplicity Assignment p-value (pCR vs. SD) p-value (pCR vs. PR) p-value (PR vs. SD) 4.24 m Threonine 0.04 0.28 0.30 1.00 s Isoleucine 0.04 0.01 0.02 2.09 m…

read more

Omics Technologies Applied in Breast Cancer Research

Feb 12, 2017 by in ONCOLOGY Comments Off on Omics Technologies Applied in Breast Cancer Research

Fig. 1.1 Relationship between gene, DNA, RNA, and protein (the central dogma of molecular biology) with omics technologies Genomics Genomics may be described as the comprehensive analysis of genes and…

read more

Nutrigenomics in Breast Cancer

Feb 12, 2017 by in ONCOLOGY Comments Off on Nutrigenomics in Breast Cancer

Fig. 6.1 Bioactive food components and its integration with various molecular streams in phenotype progression and development Table 6.1 Factors affecting nutrigenomic research and phenotype Approach Definition and factors Transcriptomics…

read more

Epigenomics of Breast Cancer

Feb 12, 2017 by in ONCOLOGY Comments Off on Epigenomics of Breast Cancer

Gene (description) Function Sample obtained Case # Methy. status Marker Reference 14-3-3-σ/stratifin (SFN) Cell cycle regulation Cell lines, tissue 20 Hyper Therapeutic Ferguson et al. [202] 14-3-3-σ/stratifin (SFN)å Cell cycle…

read more

Magnetic Nanostructures (MNS) for Cancer

Jan 31, 2017 by in ONCOLOGY Comments Off on Magnetic Nanostructures (MNS) for Cancer

Fig. 1 Size scale of MNS as compared to biomolecules. MNS can be adapted to include biomolecules, drugs, or targeting and imaging molecules to form targeted MNS theranostic agents Typically, MNS…

read more

the Nanoparticle-Protein Interface for Cancer Therapeutics

Jan 31, 2017 by in ONCOLOGY Comments Off on the Nanoparticle-Protein Interface for Cancer Therapeutics

Forces Strength Range (nm)* Specificity Main factors vdw forces Weak 0–10 No Interface complementarity H-bond Moderate <0 Partial Hydrogen donor/acceptor at interface Electrostatic forces Moderate 0–10 No Charge state, ionic…

read more

as Probes for Cancer Diagnostics

Jan 31, 2017 by in ONCOLOGY Comments Off on as Probes for Cancer Diagnostics

Fig. 1 Structure of a spherical nucleic acid (SNA)—gold nanoparticle conjugate. (Reproduced with permission from [8]) 2.1 Synthesis of SNAs We will first describe how these constructs are synthesized. SNAs can…

read more

the Tumor Microenvironment with Nanoparticles

Jan 31, 2017 by in ONCOLOGY Comments Off on the Tumor Microenvironment with Nanoparticles

Fig. 1 Schematic illustration of the major cellular and noncellular components of the tumor microenvironment (TME). The EPR effect facilitates nanoparticle (NP) accumulation. However, high interstitial fluidic pressure (IFP), pericyte coverage,…

read more
Get Clinical Tree app for offline access